{"product_id":"tirzepatide","title":"Tirzepatide","description":"\u003cp data-start=\"161\" data-end=\"535\" class=\"PDq2pG_selectionAnchorContainer\"\u003e\u003cstrong data-start=\"161\" data-end=\"535\"\u003eThis product is synthesized and distributed exclusively for in vitro laboratory experimentation and in vivo animal research models. It is strictly NOT intended for human consumption, diagnostic procedures, or therapeutic use. All handling, reconstitution, and deployment must be conducted by qualified laboratory professionals using proper personal protective equipment.\u003c\/strong\u003e\u003cspan aria-hidden=\"true\" class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-section-id=\"rzkdgm\" data-start=\"537\" data-end=\"548\"\u003eOverview\u003c\/h2\u003e\n\u003cp data-start=\"550\" data-end=\"958\"\u003eTirzepatide is a synthetic, long-acting peptide engineered as a \u003cstrong data-start=\"614\" data-end=\"726\"\u003edual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist\u003c\/strong\u003e. As the first investigational peptide designed to activate both incretin pathways simultaneously, Tirzepatide has become an important research tool for studying metabolic regulation, endocrine signalling, and receptor interactions.\u003c\/p\u003e\n\u003cp data-start=\"960\" data-end=\"1518\"\u003eIts dual receptor activity enables researchers to investigate the physiological effects of coordinated GIP and GLP-1 receptor activation on glucose metabolism, insulin signalling, energy balance, appetite regulation, lipid metabolism, and cardiometabolic physiology in both cellular systems and preclinical animal models. Tirzepatide has been extensively evaluated in large-scale clinical research programmes investigating obesity and type 2 diabetes, contributing substantially to the understanding of incretin biology. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"1520\" data-end=\"1523\"\u003e\n\u003ch2 data-section-id=\"6bvmjm\" data-start=\"1525\" data-end=\"1553\"\u003eKey Research Applications\u003c\/h2\u003e\n\u003ch3 data-section-id=\"1sdi03o\" data-start=\"1555\" data-end=\"1594\"\u003eDual Incretin Receptor Pharmacology\u003c\/h3\u003e\n\u003cp data-start=\"1596\" data-end=\"1785\"\u003eWidely utilized to investigate the combined activation of GIP and GLP-1 receptors, enabling detailed evaluation of integrated incretin signalling pathways involved in metabolic homeostasis.\u003c\/p\u003e\n\u003ch3 data-section-id=\"1a3gqfd\" data-start=\"1787\" data-end=\"1809\"\u003eGlucose Metabolism\u003c\/h3\u003e\n\u003cp data-start=\"1811\" data-end=\"1999\"\u003eStudied in experimental models to evaluate receptor-mediated regulation of glucose homeostasis, pancreatic β-cell function, insulin secretion, glucagon modulation, and insulin sensitivity.\u003c\/p\u003e\n\u003ch3 data-section-id=\"1iofk97\" data-start=\"2001\" data-end=\"2023\"\u003eEnergy Homeostasis\u003c\/h3\u003e\n\u003cp data-start=\"2025\" data-end=\"2219\"\u003eApplied in laboratory research examining mechanisms involved in energy expenditure, nutrient utilization, appetite regulation, and metabolic adaptation through dual incretin receptor signalling.\u003c\/p\u003e\n\u003ch3 data-section-id=\"htuiuv\" data-start=\"2221\" data-end=\"2247\"\u003eAdipose Tissue Biology\u003c\/h3\u003e\n\u003cp data-start=\"2249\" data-end=\"2420\"\u003eInvestigated for its influence on adipocyte physiology, lipid metabolism, adipose tissue remodelling, and cellular pathways associated with energy storage and utilization.\u003c\/p\u003e\n\u003ch3 data-section-id=\"19gqu27\" data-start=\"2422\" data-end=\"2444\"\u003eHepatic Metabolism\u003c\/h3\u003e\n\u003cp data-start=\"2446\" data-end=\"2602\"\u003eResearched to evaluate effects on hepatic glucose production, lipid metabolism, insulin responsiveness, and metabolic signalling within liver tissue models.\u003c\/p\u003e\n\u003ch3 data-section-id=\"176axtn\" data-start=\"2604\" data-end=\"2632\"\u003eCardiometabolic Research\u003c\/h3\u003e\n\u003cp data-start=\"2634\" data-end=\"2813\"\u003eUtilized in preclinical studies exploring biomarkers associated with cardiovascular physiology, inflammation, lipid metabolism, endothelial function, and overall metabolic health.\u003c\/p\u003e\n\u003chr data-start=\"2815\" data-end=\"2818\"\u003e\n\u003ch2 data-section-id=\"1cgu054\" data-start=\"2820\" data-end=\"2847\"\u003eTechnical Specifications\u003c\/h2\u003e\n\u003cp data-start=\"2849\" data-end=\"2900\"\u003e\u003cstrong data-start=\"2849\" data-end=\"2868\"\u003eClassification:\u003c\/strong\u003e Dual GIP\/GLP-1 Receptor Agonist\u003c\/p\u003e\n\u003cp data-start=\"2902\" data-end=\"2958\"\u003e\u003cstrong data-start=\"2902\" data-end=\"2919\"\u003ePeptide Type:\u003c\/strong\u003e Synthetic Long-Acting Incretin Mimetic\u003c\/p\u003e\n\u003cp data-start=\"2960\" data-end=\"3085\"\u003e\u003cstrong data-start=\"2960\" data-end=\"2981\"\u003eReceptor Targets:\u003c\/strong\u003e Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR); Glucagon-Like Peptide-1 Receptor (GLP-1R)\u003c\/p\u003e\n\u003cp data-start=\"3087\" data-end=\"3140\"\u003e\u003cstrong data-start=\"3087\" data-end=\"3102\"\u003eAppearance:\u003c\/strong\u003e White to off-white lyophilized powder\u003c\/p\u003e\n\u003cp data-start=\"3142\" data-end=\"3165\"\u003e\u003cstrong data-start=\"3142\" data-end=\"3153\"\u003ePurity:\u003c\/strong\u003e ≥98% (HPLC)\u003c\/p\u003e\n\u003cp data-start=\"3167\" data-end=\"3255\"\u003e\u003cstrong data-start=\"3167\" data-end=\"3182\"\u003eSolubility:\u003c\/strong\u003e Water-soluble following appropriate laboratory reconstitution procedures\u003c\/p\u003e\n\u003chr data-start=\"3257\" data-end=\"3260\"\u003e\n\u003ch2 data-section-id=\"yn2eex\" data-start=\"3262\" data-end=\"3309\"\u003eScientific References \u0026amp; Literature Citations\u003c\/h2\u003e\n\u003ch3 data-section-id=\"dzjdzw\" data-start=\"3311\" data-end=\"3339\"\u003eDiscovery \u0026amp; Pharmacology\u003c\/h3\u003e\n\u003cp data-start=\"3341\" data-end=\"3636\"\u003e\u003cstrong data-start=\"3341\" data-end=\"3373\"\u003eFrias, J. P., et al. (2021).\u003c\/strong\u003e \u003cem data-start=\"3374\" data-end=\"3464\"\u003eTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2).\u003c\/em\u003e \u003cstrong data-start=\"3465\" data-end=\"3500\"\u003eNew England Journal of Medicine\u003c\/strong\u003e, 385, 503–515. Supported the pharmacological characterization of dual GIP\/GLP-1 receptor agonism. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-section-id=\"1cu8crk\" data-start=\"3638\" data-end=\"3658\"\u003eObesity Research\u003c\/h3\u003e\n\u003cp data-start=\"3660\" data-end=\"3928\"\u003e\u003cstrong data-start=\"3660\" data-end=\"3697\"\u003eJastreboff, A. M., et al. (2022).\u003c\/strong\u003e \u003cem data-start=\"3698\" data-end=\"3766\"\u003eTirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).\u003c\/em\u003e \u003cstrong data-start=\"3767\" data-end=\"3802\"\u003eNew England Journal of Medicine\u003c\/strong\u003e, 387, 205–216. Demonstrated extensive investigation of tirzepatide in obesity research. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"3930\" data-end=\"4141\"\u003e\u003cstrong data-start=\"3930\" data-end=\"3963\"\u003eGarvey, W. T., et al. (2023).\u003c\/strong\u003e \u003cem data-start=\"3964\" data-end=\"4067\"\u003eTirzepatide after Intensive Lifestyle Intervention in Adults with Overweight or Obesity (SURMOUNT-3).\u003c\/em\u003e \u003cstrong data-start=\"4068\" data-end=\"4087\"\u003eNature Medicine\u003c\/strong\u003e, 29, 2909–2918. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"4386\" data-end=\"4389\"\u003e\n\u003ch2 data-section-id=\"2pxu0u\" data-start=\"4391\" data-end=\"4424\"\u003eTechnical Documentation Notice\u003c\/h2\u003e\n\u003cp data-start=\"4426\" data-end=\"4867\"\u003eThis material is supplied exclusively for laboratory research purposes. For validated technical information regarding dual incretin receptor agonists, GLP-1 and GIP receptor pharmacology, endocrine signalling pathways, and metabolic research applications, investigators are encouraged to consult peer-reviewed scientific literature and established biomedical databases, including PubMed\/NCBI, using the primary publications referenced above.\u003c\/p\u003e\n\u003cp data-start=\"4869\" data-end=\"4992\" data-is-last-node=\"\" data-is-only-node=\"\"\u003e\u003cstrong data-start=\"4869\" data-end=\"4992\" data-is-last-node=\"\"\u003eFor Research Use Only (RUO). Not for human consumption, veterinary use, clinical application, or diagnostic procedures.\u003c\/strong\u003e\u003c\/p\u003e","brand":"Seren Labs | UK | Research Peptides","offers":[{"title":"Default Title","offer_id":57622113419646,"sku":null,"price":80.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1009\/0263\/3854\/files\/ChatGPTImageJun28_2026_09_05_57PM.png?v=1783431064","url":"https:\/\/www.seren-labs.com\/products\/tirzepatide","provider":"Seren Labs | UK | Research Peptides","version":"1.0","type":"link"}